Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | KIF11 | P52732 | 2/20 | 0.49 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28335917 | 1.00 | MDM2 (0.52) | MDM2MDM4TP53KIF11SLC17A5 | |
| SCHEMBL29560536 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL3436122 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL1738641 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL5998507 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29503847 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29395463 | 0.94 | MDM4 (0.55) | MDM2MDM4TP53SLC17A5CASP3 | |
| SCHEMBL29460482 | 0.90 | MDM2 (0.54) | MDM2MDM4TP53KIF11SLC17A5 | |
| SCHEMBL21639223 | 0.90 | MDM2 (0.54) | MDM2MDM4TP53KIF11SLC17A5 | |
| SCHEMBL29400885 | 0.90 | MDM2 (0.54) | MDM2MDM4TP53KIF11SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806607-A | Site-directed cyclization method of chlorotoxin polypeptide | 哈尔滨吉象隆生物技术有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-4720093-A2 | METHODS FOR MAKING PEPTIDE CONJUGATES AND THE PRODUCT MADE THEREFROM | Decoy Therapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
| EP-4570820-A1 | LONG-ACTING INSULIN COMPOUND | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| EP-4532509-A1 | INSOLUBLE SUPPORT FOR SOLID PHASE SYNTHESIS | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-04-09 | — | — | EP | disclosed |
| CN-119751562-A | Pancreatin response bioactive peptide, nanofiber hydrogel prepared by using pancreatin response bioactive peptide and application of pancreatin response bioactive peptide | 河南中医药大学 | 2025-04-04 | — | — | CN | disclosed |
| EP-4522220-A1 | PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF | Novo Nordisk A/S (DK) | 2025-03-19 | — | — | EP | disclosed |
| WO-2024249765-A2 | METHODS FOR MAKING PEPTIDE CONJUGATES AND THE PRODUCT MADE THEREFROM | DECOY THERAPEUTICS INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4453003-A1 | HIGHLY STABLE OXYTOCIN DERIVATIVES | Universität Wien (AT) | 2024-10-30 | — | — | EP | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023104794-A1 | LINKER TECHNOLOGY FOR REDUCED RENAL RETENTION | PAUL SCHERRER INSTITUT (CH) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| CN-115806607-A | Site-directed cyclization method of chlorotoxin polypeptide | 哈尔滨吉象隆生物技术有限公司 | 2023-03-17 | — | — | CN | disclosed |
| WO-2022271810-A2 | BICYCLIC PEPTIDYL PAN-RAS INHIBITORS | OHIO STATE INNOVATION FOUNDATION (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| EP-4007593-A1 | GIPR-AGONIST COMPOUNDS | Eli Lilly and Company (US) | 2022-06-08 | — | — | EP | disclosed |
| WO-2022096636-A1 | GLP-1 PRODRUGS AND USES HEREOF | NOVO NORDISK A/S (DK) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022084486-A1 | SELF-PURIFIED NUCLEIC ACID ENCODED LIBRARIES | ETH ZURICH (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022037469-A1 | LONG-ACTING RELAXIN-2 ANALOG | 成都奥达生物科技有限公司 | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | IAPP, INSR, IDE | MDM2 3786/4885MDM4 3960/4885TP53 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.